Genes & biomarkers
Understanding gene and biomarker results
Somatic / germline · pathogenic / VUS · tissue / blood
Read the alteration, sample and clinical meaning together, beyond the gene name.
Sources checked · Introductory guide
On this page
Start with the report details
Record the gene, exact variant or fusion partner, alteration type, test date and sample. A listed drug still requires review of cancer type, stage, treatment history and access criteria; benefit is not guaranteed.[1]
Does a tumor variant mean inherited risk?
Somatic changes arise in some cells; germline variants are present from birth and may concern relatives. Tumor testing does not replace inherited-risk testing. A suspected germline finding may need counseling and confirmation with an appropriate separate sample.[2]
A VUS is not a pathogenic result
A variant of uncertain significance (VUS) lacks enough evidence for a clear harmful classification. In inherited-risk testing, a VUS alone should not determine preventive surgery or relatives’ risk. Keep the report and ask about reclassification updates.[2]
Does no finding mean no target?
Test coverage and sample quantity/quality affect results. Distinguish “not detected” from “insufficient sample” or a failed test. Depending on the situation, a blood result may need tissue follow-up. Discuss whether and when to repeat testing.[3]
Questions for your care team
- Is my finding pathogenic or a VUS, and how strong is the treatment evidence?
- Do I need tissue follow-up, repeat testing or genetic counseling?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Biomarker Testing for Cancer Treatment (opens in a new tab)
- NCI · Genetic Testing for Inherited Cancer Risk (opens in a new tab)
- ESMO · Recommendations on circulating tumour DNA assays (2022) (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.